These innovative molecules represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose https://hamzahnxvd447601.develop-blog.com/46820569/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide